Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study

Published:2018-08-20 Issue:11 Volume:25 Page:922-928
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Matsubara Nobuaki¹,Naito Yoichi¹,Nakano Kenji²,Fujiwara Yutaka³,Ikezawa Hiroki⁴,Yusa Wataru⁴,Namiki Masayuki⁴,Okude Takashi⁴,Takahashi Shunji²

Affiliation:

1. Department of Breast and Medical Oncology; National Cancer Center Hospital East; Kashiwa Chiba Japan

2. Department of Medical Oncology; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Koto-ku Tokyo Japan

3. Department of Experimental Therapeutics; National Cancer Center Hospital; Chuo-ku Tokyo Japan

4. Eisai Co., Ltd., Bunkyo-ku; Tokyo Japan

Funder

Eisai

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/iju.13776/fullpdf

Reference24 articles.

1. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N. Engl. J. Med.,2017

2. Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy;Dietz;Oncotarget,2017

3. The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma;Ho;BMC Cancer,2015

4. Resistance to targeted therapy in renal-cell carcinoma;Rini;Lancet Oncol.,2009

5. Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients;Jiménez-Valerio;Cell Rep.,2016

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice;Medical alphabet;2024-05-09

2. Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC);CPT: Pharmacometrics & Systems Pharmacology;2024-03-26

3. Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients;Therapeutic Advances in Urology;2024-01

4. Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC‐MS/MS;Thoracic Cancer;2023-09-28

5. Renal cell carcinoma management: real-world practice and challenges at a national level;Future Oncology;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3